Who
Maxine Gowen
Director
Company insider
Files Form 4 as: Director, Aclaris Therapeutics; Director, Passage Bio; Director, Merus; Director, Aceragen; Director, Akebia Therapeutics; President & CEO, Trevena; Director, Human Genome Sciences.
In numbers
- Trades disclosed
- 144
- Buys
- 7
- Sells
- 3
- Bought
- $317K
- Sold
- $271K
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 15 Feb 2008
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —13,193 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,844 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —14,414 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —16,604 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —12,240 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —7,957 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,793 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,793 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,580 at $0.00 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumAKBA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Maxine Gowen; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.